ClinicalTrials.gg

Program

fluorophosphate

Also written as “5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, “Colgate Cavity protection toothpaste” and “High SLS toothpaste”.

Its studies are mostly in Dentin Sensitivity, led by 4 companies.

Furthest: phase 3, since Sep 20, 20125 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline20 open or runningphase 2since Sep 20, 2012Sep 20, 2012none ahead
Colgate Palmolive10 open or runningphase 3since Aug 27, 2025Aug 27, 2025none ahead
Procter and Gamble10 open or runningno phasesince Nov 14, 2023Nov 14, 2023none ahead
Solventum10 open or runningno phasesince Oct 13, 2020Oct 13, 2020none ahead

Also a collaborator on its studies: 3m.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2012First study: phase 2 study in Dentin SensitivityNew to GlaxoSmithKlineGlaxoSmithKline · NCT01691560 · 140 enrolled · United States
  2. Apr 11, 2013Phase 2 study in Dentinal HypersensitivityGlaxoSmithKline · NCT01831817 · 140 enrolled · United States
  3. Oct 13, 2020Solventum's first study: no phase study in Oral Mucosal DisorderNew to SolventumSolventum · NCT04601103 · 53 enrolled · United States
  4. Nov 14, 2023Procter and Gamble's first study: no phase study in CariesNew to Procter and GambleProcter and Gamble · NCT06140758 · 12 enrolled · Australia
  5. Aug 27, 2025Colgate Palmolive's first study: phase 3 study in Dentin SensitivityNew to Colgate PalmoliveColgate Palmolive · NCT07149376 · 84 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07149376Dentin Sensitivity · United States3CompletedColgate PalmoliveOct 14, 202584
NCT06140758Caries · Australia–CompletedProcter and GambleDec 11, 202312
NCT04601103Oral Mucosal Disorder · United States–TerminatedSolventumMar 10, 202053
NCT01831817Dentinal Hypersensitivity · United States2CompletedGlaxoSmithKlineMay 2013140
NCT01691560Dentin Sensitivity · United States2CompletedGlaxoSmithKlineNov 2012140

How it is read

Names in the registry

  • “5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, 2 entries
  • “Colgate Cavity protection toothpaste”, 1 entry
  • “High SLS toothpaste”, 1 entry
  • “Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice”, 1 entry
  • “0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.